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ABSTRACT
Tight junctions are directly involved in regulating the passage of
ions and macromolecules (gate functions) in epithelial and en-
dothelial cells. The modulation of these gate functions to tran-
siently regulate the paracellular permeability of large solutes
and ions could increase the delivery of pharmacological agents
or gene transfer vectors. To reduce the inflammatory responses
caused by tight junction-regulating agents, alternative strate-
gies directly targeting specific tight junction proteins could
prove to be less toxic to airway epithelia. The apical delivery of
peptides corresponding to the first extracellular loop of occlu-
din to transiently modulate apical paracellular flux has been
demonstrated in intestinal epithelia. We hypothesized that api-
cal application of these occludin peptides could similarly mod-
ulate tight junction permeability in airway epithelia. Thus, we
investigated the effects of apically applied occludin peptide on
the paracellular permeability of molecular tracers and viral vec-
tors in well differentiated human airway epithelial cells. The
effects of occludin peptide on cellular toxicity, tight junction
protein expression and localization, and membrane integrity
were also assessed. Our data showed that apically applied
occludin peptide significantly reduced transepithelial resistance
in airway epithelia and altered tight junction permeability in a
concentration-dependent manner. These alterations enhanced
the paracellular flux of dextrans as well as gene transfer vec-
tors. The occludin peptide redistributed occludin but did not
alter the expression or distribution of ZO-1, claudin-1, or clau-
din-4. These data suggest that specific targeting of occludin
could be a better-suited alternative strategy for tight junction
modulation in airway epithelial cells compared with current
agents that modulate tight junctions.
Tight junctions are present at the apical ends of lateral
membrane surfaces of epithelial and endothelial cells and
form a series of discrete sites of apparent membrane fusion
involving the outer leaflet of the plasma membranes of adja-
cent cells. Two main functions have been attributed to the
tight junction: gate functions that regulate the passage of
ions and macromolecules through the paracellular pathway,
and fence functions that separate the apical and basolateral
membrane domains of polarized epithelia and endothelia and
prevent the intermixing of membrane-domain proteins and
lipids between the apical and the lateral membranes (Gum-
biner, 1987; Gumbiner et al., 1991). Tight junctions comprise
transmembrane proteins such as occludin (Furuse et al.,
1998), claudins (Furuse et al., 1998; Morita et al., 1999),
junctional adhesion molecule (Martin-Padura et al., 1998),
and coxsackie virus B and Ad2/5 receptor (Cohen et al.,
2001), as well as cytoplasmic molecules such as ZO-1 (Steven-
son and Goodenough, 1984), ZO-2 (Itoh et al., 1999), ZO-3
(Haskins et al., 1998), cingulin (Citi and Cordenonsi, 1998),
and 7H6 (Zhong et al., 1993). Regulatory molecules, includ-
ing tyrosine kinases, proteases, and GTPases, also colocalize
near the tight junction. Interactions between the transmem-
brane components and cytoplasmic molecules, along with the
cytoskeleton and regulatory molecules, are thought to mod-
ulate the gate and fence functions of tight junctions.
Several groups have investigated the modulation of tight
junction gate function as a method to enhance drug uptake in
intestinal epithelia (van Hoogdalem et al., 1990; Swenson et
al., 1994; Yamamoto et al., 1996). Like intestinal epithelia,
the airway epithelium is also resistant to the uptake of api-
cally delivered macromolecules. Agents that modulate tight
junctions, such as EGTA, sodium caprate, the sodium salt of
the saturated medium-chain fatty acid capric acid (C10) or
lauric acid (C12), polidocanol, and lysophosphatidyl choline
have been shown to increase the permeability of airway tight
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junction and also enhance gene transfer (Duan et al., 1998;
Parsons et al., 1998; Coyne et al., 2000, 2003; Wang et al.,
2000; Chu et al., 2001; Limberis et al., 2002). However,
delivery of these agents that alter multiple proteins in the
tight junction has been linked to inflammation in airways in
vitro and in vivo. Alternative strategies that target specific
tight junction proteins could prove to be less toxic to airway
epithelia. One such strategy directly targeted occludin to
enhance tight junction permeability to molecular tracers in a
Xenopus laevis kidney epithelial cell line A6 by basolateral
delivery of synthetic peptides corresponding to the second
extracellular loop of occludin (Wong and Gumbiner, 1997). A
similar modulation in tight junction permeability of solutes
in intestinal epithelia by apical delivery of a synthetic occlu-
din peptide has also been reported by Tavelin et al. (2003),
who showed that the conjugation of a lipoamino acid to the
occludin peptide inhibited enzymatic degradation of the pep-
tide by apical peptidases. Suppression of occludin by stable
expression of short interfering RNA with associated changes
in the gate functions of tight junctions in MDCK cells (Yu et
al., 2005) provides further evidence for the role of occludin in
tight junction functions.
Thus, occludin is a potentially good target for modulating
tight junction barrier function. Occludin is a 60-kDa inte-
gral membrane protein of tight junction fibrils that spans the
membrane four times with three cytoplasmic domains and
two extracellular loops (ECLs). The first ECL has a high
tyrosine and glycine composition, whereas the second loop is
rich in tyrosine residues. Both extracellular loops of occludin
consist solely of uncharged residues with the exception of one
or two charged residues adjacent to the membrane. Occludin
localizes to tight junctions, and its overexpression is known
to increase transepithelial resistance in mammalian epithe-
lial cells (McCarthy et al., 1996). Alteration of occludin ex-
pression has been shown to increase epithelial permeability,
and the absence of occludin from tight junctions has been
shown to have no significant affect on tight junction morphol-
ogy (Balda et al., 1996; Saitou et al., 2000).
We hypothesized that apically applied occludin peptide
could specifically modulate tight junction permeability in
airway epithelia and enhance the paracellular flux of molec-
ular tracers and viral vectors. To test this hypothesis, we
addressed the following issues: 1) whether specific targeting
of occludin in airway epithelial tight junctions by apical ap-
plication of occludin peptide could enhance paracellular per-
meability to macromolecules such as dextrans and gene
transfer vectors, 2) whether the specificity of occludin peptide
would affect the expression and distribution of other tight
junction proteins, and 3) whether specific targeting of occlu-
din could reduce the toxicity typically observed with other
tight junction modulating agents.
Materials and Methods
Occludin Peptide Synthesis. The occludin peptide OP90–103
(Fig. 1), corresponding to the first extracellular loop of human occlu-
din and consisting of amino acids 90 to 103 (DRGYGTSLLGGSVG),
was synthesized by a stepwise solid-phase procedure as described
previously (Tavelin et al., 2003). Because a previous study showed
that the conjugation of a lipoamino acid to the occludin peptide
inhibited enzymatic degradation of the peptide (Tavelin et al., 2003)
by apical peptidases, OP90–103 was conjugated to a lipophilic amino
acid moiety at the N terminus of OP90–103, resulting in C14-OP90–103.
A scrambled peptide conjugated to the same lipophilic amino acid
moiety (C14-SGLSGGTRDYGTGL-NH2) was used as a control in all
experiments.
Cell Culture. Primary airway cells from human subjects were
isolated in accordance with guidelines approved by the Committee on
the Protection of the Rights of Human Subjects. Well differentiated
human airway epithelial (WD HAE) cells were isolated from surgical
specimens, plated at a density of 2  105 cells/12 mm on Transwell-
Col inserts (0.4-m pore size; Corning Inc., Acton, MA), and main-
tained in a 50:50 mixture of light-harvesting complex basal medium
(Biofluids, Rockville, MD) and Dulbecco’s modified Eagle’s medium
with 4.5 g/l glucose supplemented with growth factors, retinoic acid,
and bovine serum albumin as described previously (Fulcher et al.,
2005). Upon reaching confluence, culture medium was aspirated
from the apical surface, and cells maintained at an air-liquid inter-
face for 3 to 4 weeks. Cultures with 10% cilia, as determined by
microscopy, and a transepithelial electrical resistance (RT) of 500
/cm2 were selected for experiments.
Electrophysiological Measurements. The RT of primary HAE
cells was monitored with an ohmmeter (EVOM; World Precision
Instruments, Sarasota, FL). Culture medium or HEPES-Ringer so-
lution was added to the apical and basolateral surfaces of WD HAE
cells in Transwell-Col inserts and incubated for 20 min at 37°C, after
which RT was measured.
Measurement of Permeability. To determine the optimal con-
centration of occludin peptide for increased tight junction permeabil-
ity, a dose-response curve was performed. Primary HAE cells were
grown on Transwell-Col inserts under air liquid interface conditions
as described previously (Fulcher et al., 2005). Occludin peptides were
applied to the apical surface of 25- to 28-day-old WD HAE cultures in
the following concentrations: 10, 30, 100, 300, and 1000 M. Control
cultures were treated with vehicle (no peptide) or 1000 M scram-
bled peptide. Transepithelial resistance (RT) was monitored with an
Fig. 1. The occludin peptide OP90–103 consisting of the amino acids DRGYGTSLLGGSVG was conjugated to a racemic 2-amino-tetradecanoic acid (C14)
moiety that was added to the N terminus of occludin peptide, resulting in C14-OP.
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ohmmeter at 10-min intervals. When RT decreased, occludin peptide
was removed from the culture medium and the recovery of RT was
monitored at 6, 24, and 48 h. The optimal concentrations of occludin
peptide (300 and 1000 M) that reduced RT rapidly (30 min) and
allowed for full recovery of RT after occludin peptide removal were
selected for subsequent experiments. Once RT had decreased, the
maximal effect of occludin peptide on the permeation of dextrans in
WD HAE cells was measured. FITC-labeled dextrans of 70 or 2000
kDa were applied at a concentration of 5 mg/ml to the lumen (source)
after removal of the occludin peptide from the culture medium. The
appearance of dextrans in the basolateral bath (sink) was measured
in 10-l samples obtained from the sink every 10 min for 60 min and
in 10 l of source samples at time 0 and at 60 min. Fluorescence was
measured in samples at 496 nm. The paracellular permeability (Papp)
coefficients were calculated as described previously (Stutts et al.,
1981).
Measurement of Transduction Efficiency. A recombinant,
first generation, E1, E3-deleted adenovirus serotype 5 vector encod-
ing a LacZ transgene (AdlacZ) and an adeno-associated vector en-
coding a green fluorescent protein (GFP) transgene (AAV2 U1a GFP)
were prepared by the University of North Carolina at Chapel Hill
Gene Therapy Vector Core. Cultures of WD HAE epithelia were
apically exposed to 1000 M scrambled peptide and 300 or 1000 M
occludin peptide for 20 min. AdlacZ at a multiplicity of infection of
300 or AAV2 U1a GFP at 500 transducing units/cell was applied to
the lumen after removal of the occludin peptide from the culture
medium. After infection for 2 h at 37°C, cells were washed with PBS
and incubated for an additional 48 h for Ad-mediated LacZ detection.
Adeno-associated vector-mediated GFP detection was performed by
fluorescent microscopy at 4 weeks post-transduction, which is the
optimal time required for synthesis of the complementary strand in
AAV expression. LacZ expression was detected by X-Gal histochem-
istry. The cultures were stained in 5-bromo-4-chloro-3-indolyl-b-D-
galactopyranoside (X-Gal) for 4 h at 37°C. To minimize background
staining, the pH of all solutions was adjusted to 8.0 with Tris buffer
(20 mM final concentration). LacZ protein levels were quantitated by
-galactosidase enzymatic analysis (Galactostar Light assay; Tropix,
Bedford, MA) according to the manufacturer’s instructions. GFP
expression was detected by fluorescent microscopy. Vehicle-treated
cultures were not exposed to scrambled peptide or occludin peptide
but received the same concentration of viral vectors as the other
treatment groups.
Measurement of Cellular Toxicity. Occludin peptide-induced
cellular toxicity was assessed by the amount of lactate dehydroge-
nase (LDH) leakage into the culture medium because an increase in
the number of cell membrane-damaged cells results in increased
LDH levels in the culture supernatant. WD HAE cells were apically
exposed to 1000 M scrambled peptide or 300 and 1000 M occludin
peptide. At 0, 6, and 24 h after treatment, culture medium was
collected, and LDH levels were measured using a commercial kit
[LDH Release Detection Kit (LDH); Roche] and analyzed according
to the manufacturer’s instructions. In brief, 100 l of cell-free super-
natant was added in duplicate to wells in a 96-well microtiter plate,
followed by the addition of 100 l of LDH assay reaction mixture.
After a 90-min incubation at room temperature, the absorbance was
read on an enzyme-linked immunosorbent assay microplate reader
at 492 nm. Background values were subtracted from each reading,
and the average absorbance for each sample was calculated. The
mean percent occludin peptide-induced LDH release for each sample
was calculated as % occludin peptide-induced LDH release  [(AB-
Sexpt  ABSlow)/(ABShigh  ABSlow)]  100, where ABSexpt i s the
mean absorbance of treated cells, ABSlow is the mean absorbance of
culture medium, and ABShigh is the mean absorbance of Triton
X-100-treated cells.
Transepithelial Permeability. For visualization of paracellular
permeability in live WD HAE cells, cultures were treated with 300 or
1000 M occludin peptide in HEPES-Ringer solution containing 2
mg/ml Texas Red-labeled 70-kDa dextran, and XZ-axis scans were
recorded by confocal microscopy at 1, 5, 10, 15, 20, and 30 min after
apical application.
Western Blotting. WD HAE cultures were apically exposed to
1000 M scrambled peptide or 300 and 1000 M occludin peptide. At
6 and 24 h after treatment, whole cell lysates from occludin peptide-
treated and control cultures were prepared with 0.1% Triton X-100
extraction buffer containing phenylmethanesulfonyl fluoride and di-
thiothreitol. Equal amounts of protein (50 g) were loaded onto 12%
Tris-glycine gels (Novex, San Diego, CA). After electrophoresis for
1.5 h at 150 V, protein was transferred to polyvinylidine difluoride
membrane at 33 V and blocked in 5% fat-free milk. Membranes were
probed with antihuman occludin (1:500), ZO-1 (1:500), claudin-1
(1:500), or claudin-4 (1:500) antibodies (Zymed Laboratories, South
San Francisco, CA) in phosphate-buffered saline-Tween 20. Proteins
were visualized with a peroxidase-conjugated secondary antibody
(1:10,000) by ECL.
Immunofluorescence and Confocal Microscopy. To deter-
mine the effects of scrambled peptide and occludin peptide on the
localization of occludin, ZO-1, claudin-1, and claudin-4, indirect im-
munofluorescence was performed on vehicle-treated, scrambled pep-
tide-treated, and occludin peptide-treated cultures at 24 h after
peptide treatment. Cells were permeabilized with methanol at
20°C for 10 min and rehydrated 3  10 min with PBS. Cells were
then blocked with 1 PBS containing 5% BSA (0.5% Triton X-100
for claudin-1 staining) for 30 min at room temperature. After three
washes in 1 PBS, antibodies to occludin, ZO-1, claudin-1, and
claudin-4 (Zymed) at a dilution of 1:1000 were added to the apical
surface for 1 h. Cells were washed with PBS and Alexa-labeled
secondary antibodies (GE Healthcare, Little Chalfont, Buckingham-
shire, UK), diluted to 10 g/ml in 10% goat serum/PBS, were added
to the apical surface and incubated for 1 h at room temperature.
Cells were postfixed in 4% paraformaldehyde and images captured
with a Zeiss 510 laser-scanning microscope (Carl Zeiss Inc., Thorn-
wood, NY).
Measurement of Fence Function. To determine the effect of
occludin peptide on membrane integrity, fence function was evalu-
ated by assessing intramembrane diffusion of BODIPY-sphingomy-
elin. The apical domains of filter-grown WD HAE cells were labeled
with BODIPY-sphingomyelin/BSA complexes that were prepared in
P-buffer (10 mM HEPES, pH 7.4, 145 mM NaCl, 1 mM sodium
pyruvate, 10 mM glucose, and 3 mM CaCl2) by slowly mixing 10 ml
of 0.8 mg/ml defatted BSA (Sigma-Aldrich, St. Louis, MO) with 200
l of BODIPY-FL-C5-sphingomyelin (Invitrogen, Carlsbad, CA)
stock solution (1 mM in dimethyl sulfoxide) under vigorous vortex-
ing. Cells were subsequently labeled with 1:2 diluted BODIPY-
sphingomyelin/BSA complexes for 10 min on ice. After the cells were
washed four times with P-buffer, they were mounted on an optical
chamber and images were captured in an XZ plane by confocal
microscopy. Occludin peptide at 1000 M was applied to the lumen
and serial images captured at 30 s and 1, 2, 5, 10, 20, and 30 min
after occludin peptide application.
Statistical Analysis. Data are presented as means 	 S.E.M. A
one-way analysis of variance and Holm-Sidak’s method for all pair-
wise multiple comparison procedures were used to determine statis-
tical significance of observed differences (P  0.05).
Results
Effect of Occludin Peptide on Permeability. To deter-
mine whether apically delivered occludin peptide could alter
permeability in WD HAE cells, the effects on transepithelial
resistance were analyzed. After apical exposure of WD HAE
to 10, 30, 100, 300, or 1000 M concentrations of occludin
peptide, RT rapidly decreased in a dose-dependent manner.
An 84% decrease in RT was induced by 1000 M occludin
peptide within 15 min of occludin peptide application (P 
0.001), whereas a 300 M concentration induced a 63% de-
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crease (P  0.001) compared with initial RT values (Fig. 2).
Rapid decreases in RT were also observed with 10, 30, and
100 M concentrations of occludin peptide. By 24 h after
occludin peptide treatment, RT recovered to normal levels in
all treatment groups, similar to the levels observed before
occludin peptide treatment. No significant changes in RT
were observed with the apical application of 300 or 1000 M
scrambled peptide, suggesting that the rapid decrease ob-
served in 300 and 1000 M occludin peptide-treated cells was
specific for the active peptide and not vehicle or lipoamino
acid induced. Our data also suggest that occludin peptide
induced a reversible and concentration-dependent decrease
in RT. Because maximum decreases in RT with full recovery
were observed with the two highest concentrations of occlu-
din peptide (300 and 1000 M), these two concentrations
were selected for all subsequent experiments.
To determine the effect of occludin peptide on tight junction
permeability to nonpolar solutes in WD HAE cells, the paracel-
lular flux of 70- or 2000-kDa FITC-labeled dextrans after apical
exposure to 300 or 1000 M occludin peptide was measured.
The basal permeability to the 70-kDa dextran was higher than
that of 2000-kDa dextran bymore than 15-fold (Fig. 3, A and B).
After treatment with 1000 M occludin peptide, permeability
was similar for both dextrans, increasing by more than 4-fold to
70-kDa dextran (P 0.001) andmore than 100-fold to 2000 kDa
dextran (P  0.001). The smaller -fold increase in paracellular
permeability for the 70-kDa dextran reflects the greater basal
permeability of cultures to 70-kDa dextran compared with the
2000-kDa dextran. At 24 h after occludin peptide application,
the paracellular permeability to both 70- and 2000-kDa dex-
trans returned to levels of permeabilitymeasured in vehicle and
scrambled peptide (1000 M) control cultures, suggesting the
increase in paracellular permeability to large dextrans is tran-
sient and reversible.
Effect of Occludin Peptide on Gene Transfer Effi-
ciency. To determine whether the occludin peptide could
increase tight junction permeability to biologically relevant
macromolecules such as gene transfer vectors, the transduc-
tion efficiencies of an adenoviral vector encoding a LacZ
transgene (AdLacZ) and an adeno-associated viral vector
encoding a GFP transgene (AAV2 U1a GFP) were evaluated
in WD HAE cells apically exposed to 300 and 1000 M
occludin peptide, the two highest concentrations that rapidly
reduced transepithelial resistance. The effect of 1000 M
scrambled peptide on AdLacZ gene transfer efficiency was
also evaluated. Similar to our results with molecular tracers,
pretreatment of WD HAE cells with 1000 M occludin pep-
tide significantly enhanced the transduction efficiencies of
both AdLacZ (multiplicity of infection 300) and AAV2 U1a
GFP (multiplicity of infection 500) vectors compared with
vehicle control cultures or 1000 M scrambled peptide-
treated cells, as assessed by X-Gal staining (Fig. 4A) and
GFP fluorescent imaging (Fig. 4B), respectively. Enzymatic
Fig. 2. Effects of occludin peptide on transepithelial resistance (RT). RT of
WD HAE cells before and after treatment with 300 and 1000 M scram-
bled peptide, 10, 30, 100, 300, and 1000 M concentrations of occludin
peptide, and vehicle (no peptide) control cultures, measured at 10-min
intervals up to 30 min, and at 60 min, 90 min, 6 h, 24 h, and 48 h. RT
recovery was monitored up to 48 h after removal of occludin peptide at the
30-min time point (n  3 cultures for 300 and 1000 M scrambled
peptide-treated cultures; n  6 for all other treatment cultures).
Fig. 3. Effects of apically delivered
occludin peptide on tight junction per-
meability to a 70-kDa FITC-labeled
dextran (A) and a 2000-kDa FITC-la-
beled dextran at 60 min and at 24 h
after occludin peptide application (B).
Permeability is expressed as paracel-
lular permeability coefficient (Papp).
Values are given as mean values 	
S.E.M. (n  3 cultures for the scram-
bled peptide-treated group; n  6 cul-
tures for all other treatment groups).
, significantly different from vehicle
and scrambled peptide-treated control
cultures.
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analysis of the level of Ad-mediated -galactosidase expres-
sion showed significantly higher levels of this protein in
cultures pretreated apically with 1000 M occludin peptide
compared with that of vehicle-treated or scrambled peptide-
treated control cultures transduced with the AdLacZ vector
alone (Fig. 4C). Vehicle control cultures and scrambled pep-
tide-treated cells had -galactosidase activity levels of 208 	
24 mU and 218 	 35 mU of -galactosidase/mg of protein,
respectively, whereas 300 M occludin peptide-treated cul-
tures had an activity of 419 	 110 mU -galactosidase/mg of
protein that exhibited a trend but were not significantly
different from vehicle- or scrambled peptide-treated cultures.
However, 1000 M occludin peptide-treated cultures exhib-
ited a significantly enhanced mean activity of 7215	 912 mU
-galactosidase/mg of protein (P  0.001). Thus, apical pre-
treatment of WD HAE cells with 1000 M occludin peptide
significantly enhanced tight junction permeability, allowing
for increased penetration of both Ad and AAV vectors to the
basolateral membrane where the viral receptors are localized
(Walters et al., 1999), resulting in greater viral binding and
internalization.
Effect of Occludin Peptide on Cellular Toxicity. To
determine whether the occludin peptide-induced alterations
in tight junction permeability resulted in cellular toxicity, we
measured lactate dehydrogenase (LDH) release into the cul-
ture media at 6 and 24 h after apical application of occludin
peptide in WD HAE cells. This assay is a relative measure of
the amount of LDH release into the media compared with
control cultures. Toxicity was observed only with the highest
occludin peptide concentration of 1000 M at 6 h post treat-
ment, with a mean occludin peptide-induced LDH release of
8%, compared with 2.25% LDH release in vehicle control
cultures (P  0.001). The 300 M concentration of occludin
peptide did not significantly increase LDH release compared
with vehicle control cultures (Fig. 5A). A similar trend was
observed in a subsequent experiment when a relative com-
parison in LDH levels was performed in scrambled peptide-
treated and 1000 M occludin peptide-treated cells at 6 and
24 h after peptide application (Fig. 5B). No difference in the
amount of LDH was observed in cells exposed to the scram-
bled peptide compared with vehicle-treated cultures. The
high baseline levels of LDH observed in the second experi-
ment could be due to by a higher concentration of cells used
or due to variations in the serum and other factors in the
culture media that may have an LDH activity. By 24 h after
treatment, LDH levels in all occludin peptide-treated cul-
tures were comparable with LDH levels in scrambled pep-
tide-treated or vehicle control cells.
Effect of Occludin Peptide on Cellular Permeability.
To determine whether the increase in permeability to dex-
trans and viral vectors was associated with increased cellular
rather than paracellular permeability, we assessed solute
permeability in live occludin peptide-treated WD HAE cul-
tures with Texas Red-labeled 70-kDa dextrans and XZ con-
focal microscopy scans. Although 70-kDA dextrans are fairly
large molecules, it has previously been demonstrated that
even larger molecular tracers such as 2000-kDa dextrans can
enter into permeabilized HAE cells (Coyne et al., 2003).
Fig. 4. Effect of apically delivered occludin peptide on gene
transfer efficiency at 48 h postinfection. A, AdlacZ trans-
duction in vehicle (no peptide) WD HAE control cultures or
after treatment with 1000 M scrambled peptide, 300 M
occludin peptide, or 1000 M occludin peptide. B, AAV2
U1a GFP transduction in vehicle WD HAE control cultures
or after treatment with 300 or 1000 M occludin peptide.
C, LacZ transgene expression assessed by a -galactosi-
dase enzymatic assay in vehicle, scrambled peptide-, and
occludin peptide-treated WD HAE cells infected with the
AdLacZ vector. Values are given as mean values 	 S.E.M.
(n  3 cultures per scrambled peptide-treated group; n  6
for all other treatment groups). , significantly different
from vehicle and scrambled peptide-treated control cul-
tures.
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Therefore, we assessed the cellular uptake of fluorescently
labeled 70-kDa dextrans in occludin peptide-treated cultures
as a measure of transcellular permeability. Our results
showed that 1000 M occludin peptide application did not
induce cellular uptake of the fluorescently labeled dextran,
because no fluorescence was detected within the epithelial
cells for up to 30 min after occludin peptide application (Fig.
6). The gradual increase in Texas Red-labeled dextrans in
lateral and basal regions surrounding the epithelial cells by
30 min after occludin peptide treatment suggests an increase
in paracellular flow of dextrans across the epithelium. No
uptake in columnar cells was detected, and infrequent up-
take into basal cells was observed. A similar trend was ob-
served with 300 M occludin peptide application, although
the extent of paracellular diffusion of fluorescently labeled
dextrans was reduced. These data suggested that apical ap-
plication of 1000 M occludin peptide does not permeabilize
the apical cell membrane and that the observed increase in
LDH release was not associated with increased cellular per-
meability to large molecular tracers. No difference in Texas
Red dextran permeability was observed with the apical ap-
plication of 1000 M scrambled peptide compared with vehi-
cle control cultures. Because it has been previously demon-
strated that the sodium salt of the medium-chain fatty acid
C10 alters tight junction barrier function in airway epithelial
cells (Coyne et al., 2003), a control experiment using C10 was
performed. Cellular uptake of the 70-kDa dextran into the
epithelium was observed within 1 min of apical application of
C10, which was not detected in occludin peptide-treated cells.
Specificity of Occludin Peptide on Tight Junction
Protein Expression and Localization. To determine
whether tight junction modulation by apical exposure of WD
HAE cells to occludin peptide was a result of the specific
effects on occludin, alterations in tight junction-associated
protein expression and distribution were assessed by West-
ern blot analyses and immunofluorescent localization of oc-
cludin, claudin-1, claudin-4, and ZO-1 in control and occludin
peptide-treated cultures. No consistent changes in the total
amounts of occludin, claudin-1, or claudin-4 were detected by
Western blotting in WD HAE cells immediately after or 24 h
after occludin peptide treatment (Fig. 7, A and B, respec-
tively). However, in WD HAE cells apically exposed to 1000
M occludin peptide, there were subtle changes in the redis-
tribution of occludin and ZO-1 immediately after occludin
peptide application, with some loss of the chicken wire occlu-
din staining pattern in the XY plane of occludin peptide-
treated but not control cultures (Fig. 7C). Alterations in the
localization of claudins-1 and -4 at a similar time point were
less prominent, if any. Immunofluorescent localization of
occludin, ZO-1, claudin-1, and claudin-4 showed no changes
in their distribution at 24 h after apical exposure to occludin
peptide. No changes in the expression or localization of these
tight junction proteins were observed in cultures apically
treated with 1000 M scrambled peptide. These data suggest
that although treatment with the occludin peptide signifi-
cantly reduces RT, it does not cause a significant cellular
redistribution in the tight junction proteins of polarized WD
HAE cells. Because ZO-1 colocalizes with occludin and is
known to bind occludin, changes in ZO-1 localization imme-
Fig. 5. Release of LDH into culture media at 6 and 24 h in vehicle-treated
WD HAE cultures or after treatment with 300 M occludin peptide or
1000 M occludin peptide (A), and in vehicle-treated, 1000 M scrambled
peptide (SP)-treated, and 1000 M occludin peptide-treated cells (B).
LDH release is represented as mean percent occludin peptide-induced
LDH release. , significant difference compared with control cultures.
Values given are mean values	 S.E.M. (n 9 cultures for vehicle control
cultures and 300 M occludin peptide-treated groups; n  3 for 1000 M
SP-treated cultures; n 15 cultures for 1000 M occludin peptide-treated
group).
Fig. 6. Imaging of 70-kDa Texas Red (TR) dextran permeability in live
WD HAE cultures at 0, 1, and 30 min after apical application of 300 or
1000 M occludin peptide and at 0, 1, and 2 min after apical application
of 30 mM C10. Phosphate-buffered saline containing 2 mg/ml Texas
Red-labeled 70-kDa dextran was apically applied to WD HAE cells, fol-
lowed by the addition of occludin peptide or C10. Scans (magnification,
400) were taken along the XZ axis at the denoted time points by
confocal microscopy. A magnified image of the paracellular flow of Texas
Red dextran at 30 min after 1000 M occludin peptide is shown below.
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diately after occludin peptide application probably resulted
from the subtle redistribution of occludin.
Effect of Occludin Peptide on Tight Junction Fence
Function. Although the redistribution of occludin immedi-
ately after occludin peptide application did not seem to be
dramatic, we further assessed the specificity of occludin dis-
ruption by measuring the fence function in occludin peptide-
treated and control cultures. The apical membrane lipids of
WD HAE cells were labeled with BODIPY-sphingomyelin,
and changes in apical membrane lipids before and after ad-
dition of vehicle, scrambled peptide, or occludin peptide were
measured. Although very subtle disruptions of the apical
membrane at 30 min after occludin peptide application may
have occurred, the fluorescent-labeled lipid generally re-
mained confined to the apical domain of the plasma mem-
brane and did not diffuse to the lateral membrane (Fig. 8),
suggesting that apical treatment of primary airway epithelia
with a high concentration of occludin peptide does not signif-
icantly alter the fence function of tight junctions, even
though occludin expression remained unaltered. A relative
comparison with an altered fence function using a medium-
chain fatty acid C10 demonstrated that no significant alter-
ations in the fence function of tight junctions occurred af-
ter occludin peptide application relative to the C10 positive
control.
Discussion
Occludin was the first transmembrane protein of tight
junctions that was identified (Furuse et al., 1993). Several
lines of evidence show that occludin plays an important role
in tight junction functions. Overexpression of chicken occlu-
din in MDCK cells was shown to increase tight junction
strand number with a corresponding elevation in transepi-
thelial resistance (McCarthy et al., 1996). A truncated form
of occludin was shown to increase tight junction permeability
to low molecular weight molecular tracers in MDCK cells
(Balda et al., 1996). Suppression of occludin by stable expres-
sion of short interfering RNA has been associated with
changes in the gate functions of tight junctions in MDCK
cells (Yu et al., 2005).
Synthetic occludin peptides provide further evidence for
their role in tight junction functions. The transepithelial
resistance of X. laevis epithelial cells in vitro was shown to
decrease by the administration of a synthetic occludin pep-
tide into the culture medium (Wong and Gumbiner, 1997).
Peptides corresponding to the first extracellular loop of oc-
cludin also increased the tight junction permeability to man-
nitol in Caco-2 cells (Tavelin et al., 2003), suggesting that
occludin is a good target for tight junction modulation. Noth-
ing is known about the effect of synthetic occludin peptides
on tight junction permeability in airway epithelial cells. In
this study, we investigated the effects of apical application of
occludin peptide on paracellular permeability in WD HAE
cells.
Our study showed that occludin peptide rapidly decreased
RT in WD HAE cells, with a significant reduction within
minutes of apical exposure to 300 or 1000 M occludin pep-
tide. The occludin peptide-induced decrease in RT was revers-
ible and returned to normal levels within 24 h, confirming
the reversibility of this strategy. The significant decrease in
RT resulted in an alteration in tight junction permeability, as
evidenced by a corresponding increase in paracellular perme-
ability to molecular tracers. Significant increases in the dif-
fusion of both low and high molecular weight dextrans were
observed in primary airway epithelia previously treated with
1000 M occludin peptide. To further test the effects of the
occludin peptide on tight junction permeability to macromol-
ecules, we measured the transduction efficiencies of adeno-
viral and adeno-associated viral vectors in WD HAE cells
pre-exposed to apical occludin peptide. Significant increases
in gene transfer mediated by both adenoviral and AAV vec-
tors were detected in occludin peptide-treated WDHAE cells.
This finding suggested that occludin peptide alters paracel-
lular permeability and increases translocation of vectors to
the basolateral membrane, resulting in enhanced binding of
viral vectors to viral receptors.
Although it has been previously demonstrated that EGTA
and the medium chain fatty acids C10 and C12 can enhance
dextran diffusion and gene transfer efficiency (Gregory et al.,
2003; Johnson et al., 2003), these agents have been shown to
have varying toxicity profiles. C12 is toxic to airway epithe-
lial cells, as evidenced by the presence of high levels of LDH
Fig. 7. Western blot detection of occludin, claudin-1, and claudin-4 ex-
pression immediately after apical application of scrambled or occludin
peptides (A) and at 24 h after exposure to scrambled and occludin pep-
tides in WD HAE cultures (B). Each lane is representative of a treatment
group (n  3 for scrambled peptide, and n  6 for all other treatment
groups). C, immunofluorescent localization of occludin, ZO-1, claudin-1,
and claudin-4 immediately after apical application of the scrambled pep-
tide or occludin peptide and at 24 h after occludin peptide application in
WD HAE cells. Vehicle-treated cultures were used as the control group.
Images (400 magnification) are representative of three cultures per
treatment group for the scrambled peptide and six cultures for the occlu-
din peptide. All images were captured under the same confocal condi-
tions. Scale bar, 20 m.
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in the culture media even at 72 h after C12 treatment. Our
data with apical delivery of occludin peptide showed mini-
mal, transient toxicity with the highest concentration of 1000
M at 6 h after treatment, which was resolved by 24 h. The
transient release of LDH raised the question whether the
increase in permeability to dextrans and viral vectors after
occludin peptide application was due to transcellular perme-
ability rather than an increase in tight junction permeability.
To address this question, we analyzed Texas Red dextran
permeability in live WD HAE cells after occludin peptide
treatment (Fig. 6). Penetration of a fluorescently labeled
70-kDa dextran in live WD HAE cultures was visualized by
scanning images in the XZ plane by confocal microscopy. The
apical application of 1000 M occludin peptide did not result
in cellular uptake throughout the epithelium, evidenced by
the absence of fluorescence within the epithelial cells even at
30 min after occludin peptide treatment. XZ images captured
at various time points after occludin peptide treatment
showed the passage of Texas Red-labeled dextrans through
the paracellular rather than the trans-cellular pathway. Sim-
ilar results were observed with 300 M occludin peptide
treatment.
When the apical membranes of the WD HAE cells were
labeled with BODIPY-sphingomyelin followed by occludin
peptide treatment, a slight dissipation of label intensity at
the apical membrane was detected in occludin peptide-
treated but not control cultures. This loss of intensity may
have accounted for the increased LDH release because the
lipophilic amino acid may transiently interact with the apical
membrane to release the peptide from the prodrug complex
(lipoamino acid plus peptide). This interaction might in-
crease the release of small molecules such as LDH but not
increase permeability to large dextrans. Although we could
not exclude the possibility that some BODIPY-sphingomyelin
was detected in the lateral membranes of occludin peptide-
treated cells because of exchange of some apical membrane
BODIPY-sphingomyelin into the P-buffer, followed by rein-
sertion into the lateral membrane, we did not readily detect
lateral diffusion of BODIPY-sphingomyelin in occludin pep-
tide-treated cells. As a control for diffusion of BODIPY-sphin-
gomyelin from the apical to the lateral surface, a relative
comparison to altered fence function induced by sodium ca-
prate (C10) was performed indicating lateral diffusion of
labeled membrane lipid in C10-treated cultures, whereas no
significant diffusion of label to the lateral membrane space
was detected on apical application of occludin peptide.
Thus, exposure of WD HAE cells to 1000 M occludin
peptide resulted in a mild, transient increase in LDH release
that was not associated with significant alterations in the
structural components of the epithelia (Figs. 6 and 8). The
high levels of LDH in the culture media of vehicle control
cells at 24 h possibly resulted from the cumulative loss of
cells in these terminally differentiated cultures that typically
senesce at 8 weeks after plating. Ciliated cells are also
highly metabolic and deplete energy stores while secreting
lactate, which may in turn affect cell viability. However, the
key point is that the LDH levels were similar in both treat-
ment and control (scrambled peptide and vehicle) groups at
24 h, suggesting that the toxicity induced by high concentra-
tions of occludin peptide is transient and quickly resolves.
To further determine whether occludin peptide application
affected the expression and distribution of tight junction
proteins, Western blot analysis and immunolocalization of
tight junction-associated proteins was performed on control
and occludin peptide-treated cultures. Immunolocalization
analysis immediately after occludin peptide application
showed a subtle redistribution of occludin and ZO-1, with no
significant changes in claudin-1 and claudin-4 localization.
Changes in the distribution of occludin and ZO-1 may be due
to specific targeting of occludin by the occludin peptide, re-
sulting in disruption of the occludin-ZO-1 complex found at
tight junctions. Although interferon- increases paracellular
permeability in intestinal epithelial cells by inducing endo-
cytosis of occludin, junctional adhesion molecule A, and clau-
din-1 (Utech et al., 2005), assessment of whether this mech-
anism occurred during enhanced paracellular permeability
after occludin peptide application was beyond the scope of
this study.
At 24 h after apical application of occludin peptide, there
was no evidence of redistribution of any of these tight junc-
tion proteins. Furthermore, no significant alterations in the
expression of occludin, claudin-1, and claudin-4 were ob-
served in Western blot analyses of WD HAE cells immedi-
ately after or 24 h after apical exposure to occludin peptide.
The lack of significant changes in these tight junction protein
components suggests that the occludin peptide-induced alter-
ations in tight junction permeability were due primarily to
specific disruption of occludin.
C14-OP90–103 used in this study is a racemic mixture of two
diastereomers, D-C14-OP90–103 and L-C14-OP90–103, which
vary in their stability (Tavelin et al., 2003). The L-isomer
containing L-2-amino dodecanoic acid (L-C14-OP) not only
Fig. 8. Analysis of intramembrane
diffusion of BODIPY-sphingomyelin
by confocal microscopy. The apical do-
mains of WD HAE cells were labeled
with BODIPY-sphingomyelin/BSA
complexes, and diffusion of lipids from
the apical to the basolateral cell do-
main were analyzed at 0, 1, 15, and 30
min in vehicle-treated cultures or af-
ter apical application of 1000 M oc-
cludin peptide. Shown are XZ images
at 400 magnification (n  3 per
treatment group). A C10-treated cul-
ture was used as a positive control.
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released OP90–103 at a 15-fold faster rate than the D-isomer
that contained D-2-amino dodecanoic acid (D-C14-OP) but also
decreased RT by 40-fold (Tavelin et al., 2003). Because only
intact OP90–103 was released by either isomer, it indicated
that the lipoamino acid moiety prevented the released
OP90–103 from degradation. In the present study, a high
concentration of occludin peptide was required to increase
paracellular permeability to dextrans and gene transfer vec-
tors. However, this high concentration resulted in modest
cellular toxicity in occludin peptide-treated WD HAE cells.
Use of the more active L-isomer of C14-OP90–103 rather than
a mixture of the both the D-C14-OP90–103 and L-C14-OP90–103
isomers may be a safer alternative to effectively modulate
tight junction permeability with minimal toxicity.
Based on our results, apical occludin peptides may repre-
sent a better class of tight junction modulators in airway
epithelial cells that specifically target the extracellular do-
mains of tight junction proteins, resulting in enhanced tight
junction permeability with minimal toxicity. Although fur-
ther studies to elucidate the safety profile of occludin peptide
in lung epithelia are needed, specific modulation of tight
junctions by occludin peptide could prove to be a valuable
alternative strategy for the efficient delivery of pharmacolog-
ical agents and viral vectors for the treatment of lung dis-
eases.
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